By Dennis Ford, CEO, LSN
The Redefining Early Stage Investments conference presents a powerful opportunity to start to create new networking opportunities with a group of investors that are probably not on your radar screen. Timing is everything. Luck is being in the right place at the right time, and knowing what to do when you get there. As a few readers may note, I have been proselytizing on how the life science investor landscape is changing, and that the real issue for life science fundraising executives is how to map the new landscape. Never daunted by a challenge, my team and I decided to do something about the dearth of compelling life science investor conferences, and host our own.
The RESI conference is poised to be one of the most important events in the life sciences space this coming fall. As I’ve discussed previously, this event is groundbreaking in that it is focused on redefining the investor landscape in early stage life sciences, and making the right connections to move the industry forward. As all of us in the industry are aware, the life science investor landscape has changed; venture capital has largely consolidated and dried up, but there is a plethora of new entities entering the space with capital to allocate.
LSN tracks these new players, and we will have a strong representation of 8 new categories of investors – senior decision-makers from some of the largest pharmaceutical & device companies, patient groups, philanthropic organizations, investment banks, and family offices will all be joining the action on September 16th. LSN fully expects 100+ of these investors to show up, and more than 60 have already confirmed. We will also be joined by next-generation technology transfer, licensing and funding experts, and there will be a free fund-raising boot camp.
I have been told by a few conference vendors they are surprised and impressed by what LSN has been able to accomplish so far. This is due mostly to our presenter and panelist line up; LSN has been able to round up under one roof a who’s who of the early stage investors and start-ups, and we still have six weeks to go until the show. I urge all biotech and medtech readers to take a look at the program, and take some time out to reeducate yourself regarding the new landscape unfolding in the life science investor arena.
On the other hand, all the sponsors, exhibitors and attendees I have talked to are interested for two reasons: one, they need access to new life science start-ups, and two, no one has mapped the new investors, and actually got them all in one venue. The RESI conference presents a powerful opportunity to start to create new networking opportunities with a group of investors that are probably not on your radar screen. I have been going to investor conferences for the past year all over the world, and the turnout is usually a few VCs with varying amounts of dry powder (capital). This conference will not only be different, but it will be ground-breaking.
Next Phase Newsletter 
Leave a comment